Validation study of a conventional enzyme immunoassay to detect HIV antibodies in oral fluid

Abstract

OBJECTIVES: The aim of our study was to validate the Genscreen HIV ½ version 2 (BIO-RAD) for detecting HIV antibodies in oral fl uid specimens (OF). BACKGROUND: The advantage of assays to detect HIV infection in OF lies in the on-site easy access and noninvasive sample collection. METHODS: Paired serum and OF were collected from 496 subjects (263 HIV-positive and 233 HIV-negative) using the Oracol test kit (Oracle Diagnostics, Inc). The quality of OF was verifi ed by measuring total IgGs using the Human IgG ELISA Quantitation Kit (Bethyl Lab.inc). All reactive OF samples were retested by Western blot HIV1/2 BLOT 2.2 (MP Biomedical, Singapore, China). RESULTS: Of 263 OF samples from participants with blood-based HIV-positive results, 259 were positive by Genscreen HIV ½ version 2 (98.48% sensitivity, 95% CI; 96.2-99.6). The 233 individuals who had a non-reactive HIV blood test were found negative on testing their OF by Genscreen HIV ½ version 2 (100% specifi city, 95% CI; 98.4-100). NPV and PPV of the assay were 98.31% (95% CI; 95.74-99.34) and 100%, (95% CI; 98.53-100.00), respectively. CONCLUSION: Genscreen HIV ½ version 2 (Bio-Rad) is a prospective method for HIV surveillance studies in hard-to-reach populations with high risk behavior using non

The Role of Gay-Related Stigma in HIV-Risk Behavior Among Sexual Minority Men in Europe

“…Exclusion criteria were adopted as follows: being younger than 18 years old; active injecting drugs; and having already participated in the study. Study bio-behavioral data collection procedures are described in detail elsewhere [38,39].…”

An Online HIV Self-Sampling Strategy for Gay, Bisexual and Other Men Who Have Sex with Men and Trans Women in Spain

“…Oral fluid samples were tested with the Genscreen HIV1+2 enzyme immunoassay (EIA) technique (BioRad Laboratories, Inc., Hercules, United States of America) [ 34 ] for the detection of HIV1+2 antibodies in the Microbiology Service. Metropolitana Norte Clinical Laboratory.…”